Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of QX005N in moderate-to-severe atopic dermatitis
ChiCTR2400082722Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QX005N in atopic dermatitis (AD) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Percentage of participants achieving EASI-75 at week 16 and Percentage of participants with IGA 0 or 1 and at least 2-point reduction at week 16. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
QX005N
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2400082722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082722.